{"id":32825,"date":"2011-08-04T17:44:31","date_gmt":"2011-08-04T09:44:31","guid":{"rendered":"http:\/\/highscope.ch.ntu.edu.tw\/wordpress\/?p=32825"},"modified":"2021-10-06T16:25:19","modified_gmt":"2021-10-06T08:25:19","slug":"%e7%94%9f%e6%8a%80%e7%94%a2%e6%a5%ad%e7%9f%ad%e8%a8%8a","status":"publish","type":"post","link":"http:\/\/localhost\/%e7%94%9f%e6%8a%80%e7%94%a2%e6%a5%ad%e7%9f%ad%e8%a8%8a\/","title":{"rendered":"\u751f\u6280\u7522\u696d\u77ed\u8a0a"},"content":{"rendered":"

\u00a0\u751f\u6280\u7522\u696d\u77ed\u8a0a<\/span>
\n\u77e5\u8b58\u901a\u8a0a\u8a55\u8ad6\u7b2c36\u671f<\/span><\/strong><\/strong>
\n\"\"<\/a><\/span><\/strong>\u00a0\u7f8e\u88fd\u85e5\u5927\u5ee0\u5206\u4eab\u5b89\u5168\u6e2c\u8a66\u8cc7\u8a0a<\/strong><\/p>\n

\u00a0\u7f8e\u570b\u5e7e\u5bb6\u5927\u85e5\u5ee0\u5df2\u540c\u610f\u5206\u4eab\u4ed6\u5011\u5982\u4f55\u9810\u6e2c\u85e5\u7269\u662f\u5426\u5b89\u5168\u7684\u8cc7\u8a0a\uff0c\u6b64\u8209\u7372\u806f\u90a6\u300c\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40\u300d(FDA)\u7a31\u8b9a\u70ba\u300c\u53f2\u7121\u524d\u4f8b\u300d\u3002<\/p>\n

\u300c\u5b89\u5168\u6e2c\u8a66\u9810\u6e2c\u806f\u76df\u300d(Predictive Safety Testing Consortium)\u4eca\u5e74\u4e09\u6708\u6210\u7acb\uff0c\u85e5\u5ee0\u6703\u54e1\u5c07\u628a\u516c\u53f8\u5167\u90e8\u7814\u767c\u7684\u751f\u7269\u6307\u6a19\u8207\u6e2c\u8a66\u8cc7\u6599\uff0c\u4ea4\u7d66\u300c\u81e8\u5e8a\u8981\u5f91\u7814\u7a76\u6240\u300d(the Critical Path Institute, C-Path)\u3002\u7814\u7a76\u6240\u8a2d\u65bc\u4e9e\u6b77\u6851\u7d0d\u5dde\u5716\u68ee(Tucson)\u5e02\uff0c\u662f\u7531\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40\u3001\u52a0\u5dde\u9580\u6d1b\u516c\u5712\u5e02(Menlo Park)\u300c\u65af\u5766\u798f\u7814\u7a76\u9662\u300d(SRI International)\u53ca\u4e9e\u6b77\u6851\u7d0d\u5927\u5b78\u51fa\u8cc7\u6210\u7acb\u7684\u975e\u71df\u5229\u7368\u7acb\u55ae\u4f4d\u3002\u00a0\u81e8\u5e8a\u8981\u5f91\u7814\u7a76\u6240\u5f59\u7de8\u8cc7\u8a0a\uff0c\u4f9b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40\u4f7f\u7528\uff1b\u85e5\u7269\u7ba1\u7406\u5c40\u5e0c\u671b\u64da\u4ee5\u5411\u5916\u754c\u63a8\u85a6\u7be9\u6ffe\u85e5\u7269\u526f\u4f5c\u7528\u7684\u6700\u4f73\u65b9\u5f0f\u3002\u5982\u6b64\u53ef\u4ee5\u7bc0\u7701\u81e8\u5e8a\u524d\u7be9\u6ffe\u7684\u6642\u9593\u8207\u91d1\u9322\u3002
\n\u300c\u5b89\u5168\u6e2c\u8a66\u9810\u6e2c\u806f\u76df\u300d\u6210\u54e1\u6709\u5fc5\u6cbb\u59a5\u3001\u8f1d\u745e\u3001\u82f1\u570b\u845b\u862d\u7d20\u53f2\u514b\u3001\u5b0c\u751f\u3001\u9ed8\u514b\u3001\u745e\u58eb\u8afe\u83ef\u3001\u52a0\u5dde\u7f85\u6c0f\u5206\u516c\u53f8\u3001\u5148\u96f6\u7b49\u85e5\u5ee0\uff0c\u9084\u6709\u65af\u5766\u798f\u7814\u7a76\u9662\u3002\u53e6\u6709\u4e09\u5bb6\u751f\u6280\u516c\u53f8\u6b63\u5728\u5354\u5546\uff0c\u6709\u610f\u52a0\u5165\u3002\u00a0<\/p>\n

\u96c6\u5718\u6210\u54e1\u80fd\u9054\u6210\u5354\u8b70\uff0c\u4fc2\u6e90\u81ea\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40\u7684\u300a\u81e8\u5e8a\u8981\u5f91\u63a8\u52d5\u6848\u300b(Critical Path Initiative)\uff0c\u4ee5\u52a0\u901f\u85e5\u7269\u7814\u767c\u3002\u91ab\u85e5\u754c\u89c0\u5bdf\u5bb6\u5f88\u7a31\u8b9a\u8a72\u63a8\u52d5\u6848\uff0c\u4f46\u4e5f\u61f7\u7591\u80fd\u4e0d\u80fd\u627e\u5230\u8db3\u5920\u7684\u652f\u6301\u6216\u8cc7\u91d1\uff0c\u4f86\u9769\u65b0\u73fe\u72c0\u3002\u53ea\u662f\uff0c\u667a\u5eab\u300c\u5feb\u901f\u91ab\u7642\u300d(FasterCures)\u4e3b\u5e2d\u8cfd\u9580(Greg Simon)\u8868\u793a\uff0c\u696d\u754c\u6587\u5316\u6539\u8b8a\uff0c\u671d\u5411\u5206\u4eab\u800c\u975e\u805a\u6582\u8cc7\u6599\u767c\u5c55\uff0c\u300c\u662f\u53ef\u559c\u7684\u7b2c\u4e00\u6b65\u3002\u5148\u63a8\u52d5\u8cc7\u8a0a\uff0c\u63a5\u8457\u9322\u5c31\u6703\u9032\u4f86\u3002\u300d\u00a0
\n<\/strong>
\n\u300c\u6c34\u6a02\u65bd\u300d\u516c\u53f8\u5728\u6d77\u5916\u4e0a\u5e02<\/strong>\u00a0<\/p>\n

\u8a2d\u5728\u7f8e\u570b\u9ebb\u5dde\u74e6\u723e\u73ca\u5e02\u7684\u300c\u6c34\u6a02\u65bd\u79d1\u6280\u300d(Aqua Bounty Technologies)\u516c\u53f8\u4e09\u6708\u5341\u4e94\u65e5\u5ba3\u5e03\uff0c\u63a8\u51fa\u50f9\u503c\u5169\u5343\u842c\u82f1\u938a\uff08\u4e09\u5343\u4e94\u767e\u842c\u7f8e\u5143\uff09\u7684\u80a1\u4efd\uff0c\u5728\u82f1\u570b\u502b\u6566\u8b49\u4ea4\u6240\u7684\u300c\u53e6\u985e\u6295\u8cc7\u5e02\u5834\u300d(Alternative Investment Market, AIM)\u92b7\u552e\u3002\u00a0
\n\u6c34\u6a02\u65bd\u516c\u53f8\u7684\u76ee\u6a19\uff0c\u5728\u52a0\u901f\u6c34\u7522\u990a\u6b96\u7684\u751f\u7522\u529b\uff0c\u90e8\u5206\u696d\u52d9\u5728\u9020\u51fa\u6210\u9577\u66f4\u5feb\u7684\u9b5a\u985e\u3002\u8a72\u516c\u53f8\u516c\u95dc\u4e8b\u52d9\u526f\u7e3d\u88c1\u9ea5\u525b\u5c3c\u683c(Joseph McGonigle)\u8868\u793a\uff0c\u6703\u8cfc\u8cb7\u80a1\u4efd\u7684\u6b50\u6d32\u6cd5\u4eba\u6295\u8cc7\u8005\uff0c\u300c\u6bd4\u8d77\u6b50\u6d32\u98df\u7269\u93c8\u88e1\u5927\u90e8\u5206\u516c\u53f8\uff0c\u5c0d\u751f\u7269\u79d1\u6280\u90fd\u66f4\u70ba\u958b\u653e\u300d\u3002\u00a0<\/p>\n

\u9ea5\u525b\u5c3c\u683c\u8868\u793a\uff0c\u5728\u6b50\u6d32\u627e\u8cc7\u91d1\u6bd4\u8f03\u5bb9\u6613\uff0c\u986f\u793a\u6d77\u5916\u300c\u6bd4\u8f03\u61c2\u5f97\u6d77\u9bae\u7522\u696d\u300d\uff0c\u9084\u6709\u6b50\u6d32\u4e00\u822c\u8f03\u9858\u610f\u6295\u8cc7\u5728\u98df\u7269\u4f9b\u61c9\u93c8\u3002\u516c\u53f8\u7ba1\u7406\u968e\u5c64\u8868\u793a\uff0c\u5f88\u9ad8\u8208\u5728\u82f1\u570b\u4e0a\u5e02\uff0c\u76ee\u524d\u80a1\u4efd\u5df2\u7d93\u5168\u6578\u627f\u552e\u3002\u65b0\u7c4c\u96c6\u7684\u8cc7\u91d1\u53ef\u4ee5\u8b93\u6c34\u6a02\u65bd\u516c\u53f8\u5728\u4e8c\u25cb\u4e00\u25cb\u5e74\u5e95\u4e4b\u524d\uff0c\u63a8\u51fa\u597d\u5e7e\u9805\u7522\u54c1\uff0c\u5305\u62ec\u65b0\u7684\u990a\u6b96\u6c34\u65cf\u75c5\u8b8a\u8a3a\u65b7\u53ca\u91ab\u7642\u6cd5\u3001\u6210\u9577\u66f4\u5feb\u7684\u9bad\u9b5a\u3001\u9c52\u9b5a\u53ca\u5433\u90ed\u9b5a\uff1b\u90a3\u4e9b\u9b5a\u8ddf\u6b63\u5e38\u9b5a\u76f8\u6bd4\uff0c\u82b1\u540c\u6a23\u6642\u9593\u53ef\u4ee5\u5927\u4e0a\u4e00\u500d\u3002
\n\u00a0
\n\u8a72\u516c\u53f8\u6700\u8fd1\u5c07\u90a3\u4e9b\u57fa\u56e0\u6539\u9020\u9b5a\uff0c\u5411\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40\u63d0\u51fa\u7533\u8acb\uff0c\u5e0c\u671b\u4eca\u5e74\u7a0d\u5f8c\u80fd\u7372\u51c6\uff1b\u4f30\u8a08\u5728\u4e8c\u25cb\u25cb\u4e5d\u5e74\u4e0a\u5e02\uff0c\u5730\u9ede\u5728\u7f8e\u570b\u53ca\u4e9e\u6d32\u3002\u8a72\u516c\u53f8\u76ee\u524d\u6c92\u6709\u5728\u6b50\u6d32\u92b7\u552e\u9b5a\u985e\u7684\u8a08\u756b\u3002\u00a0
\n<\/strong><\/p>\n

\u5fae\u8edf\u652f\u6301\u751f\u7269\u8cc7\u8a0a\u7814\u767c<\/strong>\u00a0<\/p>\n

\u5fae\u8edf\u516c\u53f8\u6700\u8fd1\u5ba3\u5e03\u5275\u8a2d\u65b0\u7684\u7814\u7a76\u6848\uff0c\u7a31\u70ba\u300c\u751f\u7269\u8cc7\u8a0a\u79d1\u6280\u806f\u76df\u300d(the BioIT Alliance)\u3002\u9019\u500b\u806f\u76df\u662f\u4e00\u500b\u7531\u5fae\u8edf\u5e36\u982d\u7684\u5de5\u4f5c\u7fa4\uff0c\u53c3\u8207\u8005\u5305\u62ec\u5341\u4e8c\u500b\u4ee5\u4e0a\u7684\u5b78\u8853\u6a5f\u69cb\u53ca\u516c\u53f8\uff0c\u5176\u4e2d\u6709\u52a0\u5dde\u8056\u5854\u514b\u62c9\u62c9\u7684\u827e\u83f2\u6676\u7247\u516c\u53f8(Affymetrix)\u3001\u4f5b\u65af\u7279\u5e02\u7684\u300c\u61c9\u7528\u751f\u547d\u7cfb\u7d71\u300d\u516c\u53f8(Applied Biosystems)\u3001\u8056\u5730\u7259\u54e5\u5e02\u300c\u963f\u7c73\u6797\u88fd\u85e5\u300d\u516c\u53f8(Amylin Pharmaceuticals)\u3002\u00a0<\/p>\n

\u9019\u500b\u5de5\u4f5c\u7fa4\u5c07\u81f4\u529b\u65bc\u5e7e\u9805\u300c\u6982\u5ff5\u8b49\u660e\u300d\u7684\u5c08\u6848\u3002\u83ef\u76db\u9813\u5dde\u67ef\u514b\u862d\u5e02\u300cOVP\u5275\u6295\u5408\u5925\u516c\u53f8\u300d(OVP Venture Partners)\u6709\u53c3\u8207\u806f\u76df\uff0c\u6700\u8fd1\u624d\u6295\u8cc7\u6578\u9805\u751f\u7269\u8cc7\u8a0a\u65b9\u6848\u3002\u80a1\u6771\u52d2\u83f2\u4f5b(Rick LeFaivre)\u6307\u51fa\uff0c\u7531\u806f\u76df\u7684\u89c0\u9ede\u770b\u4f86\uff0c\u5e02\u5834\u4e26\u4e0d\u5927\uff0c\u662f\u4e00\u500b\u7b56\u7565\u6027\u7684\u65b0\u8208\u5e02\u5834\u3002\u5e7e\u500b\u6708\u524d\uff0c\u672c\u5de5\u4f5c\u7fa4\u5c55\u958b\u7b2c\u4e00\u9805\u5c08\u6848\uff0c\u6295\u5165\u300c\u65af\u594e\u666e\u65af\u7814\u7a76\u9662\u300d(the Scripps Research Institute)\u7a31\u505a\u300c\u5354\u529b\u5f0f\u5206\u5b50\u74b0\u5883\u300d(Collaborative Molecular Environment)\u7684\u65b9\u6848\uff0c\u65e8\u5728\u8a2d\u8a08\u51fa\u8cc7\u6599\u652b\u53d6\u3001\u986f\u50cf\u3001\u52a0\u4ee5\u8a3b\u91cb\u53ca\u5efa\u6a94\u7684\u65b9\u6cd5\u3002\u00a0<\/p>\n

\u5eb7\u4e43\u72c4\u514b\u5dde\u53f2\u4e39\u798f\u5e02\u79d1\u6280\u5e02\u5834\u7814\u7a76\u6a5f\u69cb\u300c\u8cc8\u7d0d\u300d(Gartner)\u7684\u751f\u547d\u79d1\u5b78\u5206\u6790\u5bb6\u7f85\u8332\u5a01\u723e(Carol Rozwell)\u8868\u793a\uff0c\u7d50\u76df\u958b\u767c\u751f\u547d\u8cc7\u8a0a\u8edf\u9ad4\u7684\u4f5c\u6cd5\u6108\u4f86\u6108\u666e\u904d\uff0c\u9996\u5ea6\u51fa\u73fe\u5728\u56db\u5e74\u524d\uff0c\u7531IBM\u516c\u53f8\u63d0\u51fa\u985e\u4f3c\u7b56\u7565\u3002\u00a0<\/p>\n

\u5c08\u6848\u660e\u793a\u7684\u76ee\u6a19\u5728\u8cc7\u6599\u8490\u96c6\u8207\u4ea4\u63db\u7684\u6a19\u6e96\u5316\uff0c\u56e0\u70ba\u76ee\u524d\u4f7f\u7528\u7684\u6709\u597d\u5e7e\u7a2e\u5354\u5b9a\uff0c\u5c40\u9650\u4e86\u8cc7\u6599\u7684\u53ef\u7528\u6027\u3002\u53ea\u662f\u7f85\u8332\u5a01\u723e\u4ecd\u62b1\u6301\u61f7\u7591\u614b\u5ea6\uff0c\u4ed6\u4e0d\u8a8d\u70ba\u9019\u7a2e\u65b9\u5f0f\u53ef\u4ee5\u63a8\u9032\u8cc7\u8a0a\u7684\u6a19\u6e96\u5316\uff1b\u5fae\u8edf\u7684\u5c08\u6848\u53ef\u4ee5\u8b93\u53c3\u8207\u806f\u76df\u5925\u4f34\u7684\u7522\u54c1\u7522\u751f\u4ea4\u4e92\u4f5c\u7528\uff0c\u4f46\u662f\u8981\u843d\u5be6\u6210\u5f88\u958b\u653e\u7684\u4f5c\u6cd5\uff0c\u9084\u662f\u5f88\u56f0\u96e3\u3002\u00a0
\n<\/strong>
\n\u82f1\u570b\u57fa\u91d1\u6295\u5165\u4e2d\u570b\u751f\u7269\u88fd\u85e5<\/strong>\u00a0<\/p>\n

\"\"<\/a>\u7e3d\u516c\u53f8\u5728\u82f1\u570b\u502b\u6566\u7684\u5275\u6295\u516c\u53f8\u300c\u745e\u672c\u79d1\u6280\u300d(Reabourne Technology)\u5df2\u6210\u7acb\u300c\u4e2d\u570b\u751f\u547d\u79d1\u5b78\u6295\u8cc7\u57fa\u91d1\u300d(China Life Science Investment Fund)\uff0c\u4ee5\u4fbf\u5728\u4e2d\u570b\u751f\u7522\u65b0\u7684\u5916\u570b\u5c08\u5229\u85e5\u5291\u8207\u91ab\u7642\u8a2d\u5099\u3002\u64da\u745e\u672c\u7684\u6295\u8cc7\u7d93\u7406\u5f6d\u61f7\u4e2d\u8868\u793a\uff0c\u6a19\u6e96\u7684\u904b\u4f5c\u6a21\u7bc4\uff0c\u4e43\u5728\u53d6\u5f97\u751f\u7522\u8a31\u53ef\u8b49\uff0c\u88fd\u9020\u897f\u65b9\u570b\u5bb6\u767c\u7d66\u5c08\u5229\u7684\u751f\u6280\u85e5\u7269\u53ca\u91ab\u7642\u8a2d\u5099\uff0c\u63a5\u4e0b\u4f86\u904b\u7528\u8a31\u53ef\u8b49\u4f5c\u70ba\u8cc7\u91d1\uff0c\u8ddf\u4e2d\u570b\u7576\u5730\u85e5\u5ee0\u7d50\u6210\u5408\u8cc7\u4f01\u696d\u3002\u00a0
\n\u76ee\u524d\u4e2d\u570b\u7684\u85e5\u54c1\u767e\u5206\u4e4b\u4e5d\u5341\u4e03\u662f\u5c08\u5229\u671f\u5df2\u904e\u7684\u5b78\u540d\u85e5\u3002\u5f6d\u61f7\u4e2d\u8868\u793a\uff0c\u5728\u4e2d\u570b\u751f\u7522\u7684\u5c08\u5229\u85e5\u54c1\u5f88\u5c11\uff0c\u539f\u56e0\u5728\u897f\u65b9\u570b\u5bb6\u7684\u85e5\u5ee0\u4e0d\u719f\u6089\u4e2d\u570b\uff0c\u4e5f\u5f88\u5728\u610f\u4fdd\u8b77\u81ea\u5df1\u7684\u667a\u6167\u8ca1\u7522\u3002\u56e0\u70ba\u897f\u65b9\u516c\u53f8\u5c0d\u4e2d\u570b\u85e5\u5ee0\u7f3a\u4e4f\u4fe1\u5fc3\uff0c\u6240\u4ee5\u4e2d\u570b\u7684\u85e5\u5ee0\u5fc5\u9808\u7d66\u4ed8\u9ad8\u5f97\u591a\u7684\u50f9\u683c\uff0c\u624d\u80fd\u53d6\u5f97\u751f\u7522\u6388\u6b0a\u3002\u00a0<\/p>\n

\u5f6d\u61f7\u4e2d\u8868\u793a\uff0c\u900f\u904e\u8a72\u516c\u53f8\u57fa\u91d1\u7576\u4e2d\u9593\u4eba\uff0c\u53ef\u4ee5\u514b\u670d\u5f88\u591a\u554f\u984c\u3002\u4ed6\u4e5f\u8868\u793a\uff0c\u57fa\u91d1\u5df2\u53d6\u5f97\u597d\u5e7e\u9805\u66a2\u92b7\u751f\u7269\u79d1\u6280\u7522\u54c1\u7684\u751f\u7522\u6388\u6b0a\uff0c\u800c\u4e14\u8a72\u57fa\u91d1\u9810\u8a08\u7e3d\u6578\u7684\u4e00\u5104\u4e94\u5343\u842c\u7f8e\u5143\uff0c\u5df2\u7d93\u7c4c\u5230\u4e86\u516d\u5343\u842c\u3002\u00a0<\/p>\n

\u5317\u4eac\u88fd\u85e5\u696d\u6295\u8cc7\u6a5f\u69cb\u300c\u5929\u884c\u5065\u300d\u516c\u53f8\u526f\u7e3d\u88c1\u5f90\u6771\u9b6f\u8868\u793a\uff0c\u6210\u7acb\u57fa\u91d1\u7684\u60f3\u6cd5\u6975\u5176\u53ef\u884c\uff0c\u800c\u4e14\u5f88\u6709\u524d\u666f\uff0c\u4f46\u6700\u5927\u7684\u6311\u6230\uff0c\u5728\u5f6d\u61f7\u4e2d\u662f\u5426\u80fd\u627e\u5230\u53ef\u4ee5\u4fe1\u8cf4\u7684\u4e2d\u570b\u5408\u4f5c\u5925\u4f34\uff0c\u4f86\u751f\u7522\u3001\u8a3b\u518a\u4e26\u92b7\u552e\u4ed6\u5011\u9078\u64c7\u7684\u897f\u65b9\u5c08\u5229\u85e5\u7269\u3002\u00a0
\n\u00a0<\/strong>\u00a0
\n\u6b50\u7f8e\u5408\u4f5c\u85e5\u7269\u767c\u5c55\u6d41\u7a0b<\/strong>\u00a0<\/p>\n

\u6b50\u6d32\u5171\u540c\u9ad4\u85e5\u7269\u8a55\u5be9\u59d4\u54e1\u6703(The European Agency for the Evaluation of Medicinal Products, EMEA)\u8207\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40(US Food and Drug Administration, FDA)\u5df2\u5ba3\u5e03\uff0c\u96d9\u65b9\u65bc\u4e8c\u25cb\u25cb\u4e94\u5e74\u5143\u6708\u6572\u5b9a\u7684\u8a08\u756b\u5c55\u671f\u4e00\u5e74\u3002\u00a0
\n\u4f9d\u8a72\u8a08\u756b\uff0c\u5404\u751f\u7269\u516c\u53f8\u53ef\u4ee5\u5e73\u884c\u53d6\u5f97\u96d9\u65b9\u91ab\u85e5\u6cd5\u898f\u6a5f\u69cb\u7684\u79d1\u5b78\u5efa\u8b70\u3002\u96d9\u65b9\u5408\u4f5c\u7684\u7126\u9ede\uff0c\u5c24\u5176\u5074\u91cd\u5728\u75ab\u82d7\u3001\u5152\u7ae5\u85e5\u7269\u3001\u7f55\u898b\u75c5\u75c7\u85e5\u65b9\u3001\u816b\u7624\u5b78\u53ca\u85e5\u7269\u57fa\u56e0\u9ad4\u5b78\u3002EMEA\u767c\u8a00\u4eba\u5967\u90b1\u5340(Martin Harvey Allchurch)\u8868\u793a\uff0c\u53bb\u5e74\uff0c\u6709\u56db\u5bb6\u516c\u53f8\u5b8c\u6210\u5e73\u884c\u5efa\u8b70\u6d41\u7a0b\uff0c\u53e6\u6709\u56db\u5bb6\u9084\u5728\u7533\u8acb\u4e2d\uff1b\u7531\u5169\u5927\u85e5\u7269\u6cd5\u898f\u6a5f\u69cb\u63d0\u4f9b\u5efa\u8b70\uff0c\u53ef\u4ee5\u7701\u4e0b\u6642\u9593\u8207\u91d1\u9322\u3002\u00a0<\/p>\n

\u5967\u90b1\u5340\u8868\u793a\uff0cFDA\u8ddfEMEA\u5408\u4f5c\uff0c\u63d0\u4f9b\u5efa\u8b70\u7d66\u5ee0\u5546\uff0c\u56e0\u6b64\u4e92\u52d5\u5f97\u66f4\u52a0\u5bc6\u5207\uff0c\u4e26\u5728\u5e55\u5f8c\u63a8\u52d5\u6700\u512a\u5148\u7684\u4e8b\u9805\uff0c\u6bd4\u5982\u7814\u767c\u764c\u75c7\u751f\u7269\u6307\u6a19\u3002\u5169\u5bb6\u6a5f\u69cb\u7684\u5b98\u54e1\u6307\u51fa\uff0c\u5408\u4f5c\u6848\u96d6\u7136\u4ecd\u6709\u4e9b\u5f8c\u52e4\u548c\u5be6\u52d9\u7684\u7d30\u7bc0\u6709\u5f85\u78e8\u5408\uff0c\u4f46\u5230\u6700\u5f8c\uff0c\u9019\u7a2e\u5408\u4f5c\u5f88\u53ef\u80fd\u6210\u70ba\u96d9\u908a\u7684\u4f8b\u884c\u4e8b\u52d9\u3002<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

\u00a0\u751f\u6280\u7522\u696d\u77ed\u8a0a \u77e5\u8b58\u901a\u8a0a\u8a55\u8ad6\u7b2c36\u671f \u00a0\u7f8e\u88fd\u85e5\u5927\u5ee0\u5206\u4eab\u5b89\u5168\u6e2c\u8a66\u8cc7\u8a0a \u00a0\u7f8e\u570b\u5e7e\u5bb6\u5927\u85e5\u5ee0\u5df2\u540c\u610f\u5206\u4eab\u4ed6\u5011\u5982\u4f55\u9810\u6e2c\u85e5\u7269…<\/p>\n","protected":false},"author":50,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[165,171,5930],"tags":[3525],"class_list":["post-32825","post","type-post","status-publish","format-standard","hentry","category-kreview00","category-kreview06","category-5930","tag-3525","avhec_catgroup-all","loop-entry","cat-165","cat-171","cat-5930","no-thumbnail"],"views":3476,"_links":{"self":[{"href":"http:\/\/localhost\/wp-json\/wp\/v2\/posts\/32825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/localhost\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/localhost\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/localhost\/wp-json\/wp\/v2\/users\/50"}],"replies":[{"embeddable":true,"href":"http:\/\/localhost\/wp-json\/wp\/v2\/comments?post=32825"}],"version-history":[{"count":1,"href":"http:\/\/localhost\/wp-json\/wp\/v2\/posts\/32825\/revisions"}],"predecessor-version":[{"id":88171,"href":"http:\/\/localhost\/wp-json\/wp\/v2\/posts\/32825\/revisions\/88171"}],"wp:attachment":[{"href":"http:\/\/localhost\/wp-json\/wp\/v2\/media?parent=32825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/localhost\/wp-json\/wp\/v2\/categories?post=32825"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/localhost\/wp-json\/wp\/v2\/tags?post=32825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}